Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome

Journal of Pathology

Volumn 186, Issue 3, 1998, Pages 300-305

  Kumar Singh, Samir ^a   Jacobs, Werner ^a   Dhaene, Karl ^a   Weyn, Barbara ^a   Bogers, Johannes ^a   Weyler, Joost ^a   Van Marck, Eric ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Differentiation; Heparan sulphate proteoglycans; hFGF; Mesothelioma; Perlecan; Prognosis; Syndecan 1; WT1

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MONOCLONAL ANTIBODY; PERLECAN; SYNDECAN;

ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; NEOVASCULARIZATION (PATHOLOGY); NEPHROBLASTOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BLOTTING, WESTERN; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; DNA-BINDING PROTEINS; EPITHELIUM; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; NEOVASCULARIZATION, PATHOLOGIC; PRECIPITIN TESTS; PROGNOSIS; PROTEOGLYCANS; SURVIVAL RATE; SYNDECAN-1; SYNDECANS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 0031789410     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q     Document Type: Article

References (30)

1. Rapraeger A, Bernfield M. Cell surface proteoglycan of mammary epithelial cells. Protease releases a heparan sulfate-rich ectodomain from a putative membrane-anchored domain. J Biol Chem 1985; 260: 4103-4109.
2. Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem 1992; 267: 8544-8557.
3. Salmivirta M, Heino J, Jalkanen M. Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. J Biol Chem 1992; 267: 17 606-17 610.
4. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10 931-10 934.
5. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705-1708.
6. Mali M, Andtfolk H, Miettinen HM, Jalkanen M. Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 1994; 269: 27 795-27 798.
7. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994; 79: 1005-1013.
8. Iozzo RV, Cohen IR, Grassel S, Murdoch AD. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994; 302: 625-639.
9. Mali M, Andtfolk H, Miettinen HM, Jalkanen M. Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 1994; 269: 27 795-27 798.
10. Inki P, Joensuu H, Grenman R, Klemi P, Jalkanen M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 1994; 70: 319-323.
11. Kumar-Singh S, Vermeulen PB, Weyler J. et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997; 182: 211-216.
12. Kumar-Singh S, Martin MJ, Weyler J, et al. Basic-FGF has a prognostic value in malignant mesothelioma and mesothelioma cell lines overexpress VEGF and bFGF. Fourth International Mesothelioma Conference. 1997. Abstract.
13. Madden SL, Cook DM, Morris JF, Gashier A, Sukhatme VP, Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 1991; 253: 1550-1553.
14. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 1991; 11: 1707-1712.
15. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997; 181: 67-74.
16. Vainio S, Lehtonen E, Jalkanen M, Bernfield M, Saxen L. Epithelial-mesenchymal interactions regulate the stage-specific expression of a cell surface proteoglycan, syndecan, in the developing kidney. Dev Biol 1989; 134: 382-391.
17. Vainio S, Thesleff I. Coordinated induction of cell proliferation and syndecan expression in dental mesenchyme by epithelium: evidence for diffusible signals. Dev Dyn 1992; 194: 105-117.
18. Cook DM, Hinkes MT, Bernfield M, Rauscher FJ. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996; 13: 1789-1799.
19. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 318-323.
20. Couchman JR, Ljubimov AV. Mammalian tissue distribution of a large heparan sulfate proteoglycan detected by monoclonal antibodies. Matrix 1989; 9: 311-321.
21. Ferriola PC, Stewart W. Fibronectin expression and organization in mesothelial and mesothelioma cells. Am J Physiol 1996; 271: L804-L812.
22. Cohen IR, Murdoch AD, Naso MF, Marchetti D, Berd D, Iozzo RV. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 1994; 54: 5771-5774.
23. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107: 743-751.
24. Bielefeldt OH, Fitzpatrick DR, Marzo AL, et al. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994; 39: 347-359.
25. Elenius K, Maatta A, Salmivirta M, Jalkanen M. Growth factors induce 3T3 cells to express bFGF-binding syndecan. J Biol Chem 1992; 267: 6435-6441.
26. Sneed TB, Stanley DJ, Young LA, Sanderson RD. Interleukin-6 regulates expression of the syndecan-1 proteoglycan on B lymphoid cells. Cell Immunol 1994; 153: 456-467.
27. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992; 313: 355-364.
28. Kumar-Singh S, Van Marck E. Differentition and differentiating patterns in mesothelioma. In: Peters GA, Peters B, eds. Sourcebook on Asbestos Disease. Vol 16. Charlottesville, USA: Lexus, 1998; 213-284.
29. Langerak AW, Williamson KA, Miyagawa K, Hagemeijer A, Versnel MA, Hastie ND. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosomes Cancer 1995; 12: 87-96.
30. Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 1995; 6: 559-576.